Selected research
Industry Research
Biomarker Clinical Phase Outsourcing Services Industry Research Report 2026
Market perspective
The global Biomarker Clinical Phase Outsourcing Services market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biomarker Clinical Phase Outsourcing Services market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biomarker Clinical Phase Outsourcing Services market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biomarker Clinical Phase Outsourcing Services market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biomarker Clinical Phase Outsourcing Services include ICON plc, Fujirebio lnc, Charles River Laboratories International,Inc., Laboratory Corporation of America Holdings, Parexel lnternational Corporation, Proteome Sciences plc, Eurofins Scientific, Wuxi AppTec Co., Ltd. and NorthEast BioAnalytical Laboratories LLC., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biomarker Clinical Phase Outsourcing Services market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biomarker Clinical Phase Outsourcing Services.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biomarker Clinical Phase Outsourcing Services Market by Company
ICON plc
Fujirebio lnc
Charles River Laboratories International,Inc.
Laboratory Corporation of America Holdings
Parexel lnternational Corporation
Proteome Sciences plc
Eurofins Scientific
Wuxi AppTec Co., Ltd.
NorthEast BioAnalytical Laboratories LLC.
Celerion, Inc.
GenScript ProBio Co.,Ltd.
Biomarker Clinical Phase Outsourcing Services Segment by Type
Predictive Biomarker
Prognostic Biomarker
Safety Biomarker
Surrogate Endpoints
Biomarker Clinical Phase Outsourcing Services Segment by Application
Pharmaceutical Companies
Biotechnology Companies
Others
Biomarker Clinical Phase Outsourcing Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomarker Clinical Phase Outsourcing Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biomarker Clinical Phase Outsourcing Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomarker Clinical Phase Outsourcing Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biomarker Clinical Phase Outsourcing Services companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Predictive Biomarker
- Prognostic Biomarker
- Safety Biomarker
- Surrogate Endpoints
Applications
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Companies covered
- ICON plc
- Fujirebio lnc
- Charles River Laboratories International,Inc.
- Laboratory Corporation of America Holdings
- Parexel lnternational Corporation
- Proteome Sciences plc
- Eurofins Scientific
- Wuxi AppTec Co., Ltd.
- NorthEast BioAnalytical Laboratories LLC.
- Celerion, Inc.
- GenScript ProBio Co.,Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biomarker Clinical Phase Outsourcing Services by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Predictive Biomarker
- 2.2.3 Prognostic Biomarker
- 2.2.4 Safety Biomarker
- 2.2.5 Surrogate Endpoints
- 2.3 Biomarker Clinical Phase Outsourcing Services by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Biotechnology Companies
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Biomarker Clinical Phase Outsourcing Services Breakdown Data by Type
- 3.1 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size by Type (2021-2026)
- 3.2 Global Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Type (2027-2032)
4 Biomarker Clinical Phase Outsourcing Services Breakdown Data by Application
- 4.1 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size by Application (2021-2026)
- 4.2 Global Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biomarker Clinical Phase Outsourcing Services Market Perspective (2021-2032)
- 5.2 Global Biomarker Clinical Phase Outsourcing Services Growth Trends by Region
- 5.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biomarker Clinical Phase Outsourcing Services Historic Market Size by Region (2021-2026)
- 5.2.3 Biomarker Clinical Phase Outsourcing Services Forecasted Market Size by Region (2027-2032)
- 5.3 Biomarker Clinical Phase Outsourcing Services Market Dynamics
- 5.3.1 Biomarker Clinical Phase Outsourcing Services Industry Trends
- 5.3.2 Biomarker Clinical Phase Outsourcing Services Market Drivers
- 5.3.3 Biomarker Clinical Phase Outsourcing Services Market Challenges
- 5.3.4 Biomarker Clinical Phase Outsourcing Services Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biomarker Clinical Phase Outsourcing Services Players by Revenue
- 6.1.1 Global Top Biomarker Clinical Phase Outsourcing Services Players by Revenue (2021-2026)
- 6.1.2 Global Biomarker Clinical Phase Outsourcing Services Revenue Market Share by Players (2021-2026)
- 6.2 Global Biomarker Clinical Phase Outsourcing Services Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biomarker Clinical Phase Outsourcing Services Head Office and Area Served
- 6.4 Global Biomarker Clinical Phase Outsourcing Services Players, Product Type & Application
- 6.5 Global Biomarker Clinical Phase Outsourcing Services Manufacturers Established Date
- 6.6 Global Biomarker Clinical Phase Outsourcing Services Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 7.2 North America Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 7.4 North America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 8.2 Europe Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 8.4 Europe Biomarker Clinical Phase Outsourcing Services Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 9.2 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 10.2 South America Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 10.4 South America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 11.2 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 ICON plc
- 12.1.1 ICON plc Company Information
- 12.1.2 ICON plc Business Overview
- 12.1.3 ICON plc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.1.4 ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.1.5 ICON plc Recent Developments
- 12.2 Fujirebio lnc
- 12.2.1 Fujirebio lnc Company Information
- 12.2.2 Fujirebio lnc Business Overview
- 12.2.3 Fujirebio lnc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.2.4 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.2.5 Fujirebio lnc Recent Developments
- 12.3 Charles River Laboratories International,Inc.
- 12.3.1 Charles River Laboratories International,Inc. Company Information
- 12.3.2 Charles River Laboratories International,Inc. Business Overview
- 12.3.3 Charles River Laboratories International,Inc. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.3.4 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.3.5 Charles River Laboratories International,Inc. Recent Developments
- 12.4 Laboratory Corporation of America Holdings
- 12.4.1 Laboratory Corporation of America Holdings Company Information
- 12.4.2 Laboratory Corporation of America Holdings Business Overview
- 12.4.3 Laboratory Corporation of America Holdings Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.4.4 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.4.5 Laboratory Corporation of America Holdings Recent Developments
- 12.5 Parexel lnternational Corporation
- 12.5.1 Parexel lnternational Corporation Company Information
- 12.5.2 Parexel lnternational Corporation Business Overview
- 12.5.3 Parexel lnternational Corporation Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.5.4 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.5.5 Parexel lnternational Corporation Recent Developments
- 12.6 Proteome Sciences plc
- 12.6.1 Proteome Sciences plc Company Information
- 12.6.2 Proteome Sciences plc Business Overview
- 12.6.3 Proteome Sciences plc Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.6.4 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.6.5 Proteome Sciences plc Recent Developments
- 12.7 Eurofins Scientific
- 12.7.1 Eurofins Scientific Company Information
- 12.7.2 Eurofins Scientific Business Overview
- 12.7.3 Eurofins Scientific Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.7.4 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.7.5 Eurofins Scientific Recent Developments
- 12.8 Wuxi AppTec Co., Ltd.
- 12.8.1 Wuxi AppTec Co., Ltd. Company Information
- 12.8.2 Wuxi AppTec Co., Ltd. Business Overview
- 12.8.3 Wuxi AppTec Co., Ltd. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.8.4 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.8.5 Wuxi AppTec Co., Ltd. Recent Developments
- 12.9 NorthEast BioAnalytical Laboratories LLC.
- 12.9.1 NorthEast BioAnalytical Laboratories LLC. Company Information
- 12.9.2 NorthEast BioAnalytical Laboratories LLC. Business Overview
- 12.9.3 NorthEast BioAnalytical Laboratories LLC. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.9.4 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.9.5 NorthEast BioAnalytical Laboratories LLC. Recent Developments
- 12.10 Celerion, Inc.
- 12.10.1 Celerion, Inc. Company Information
- 12.10.2 Celerion, Inc. Business Overview
- 12.10.3 Celerion, Inc. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.10.4 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.10.5 Celerion, Inc. Recent Developments
- 12.11 GenScript ProBio Co.,Ltd.
- 12.11.1 GenScript ProBio Co.,Ltd. Company Information
- 12.11.2 GenScript ProBio Co.,Ltd. Business Overview
- 12.11.3 GenScript ProBio Co.,Ltd. Revenue in Biomarker Clinical Phase Outsourcing Services Business (2021-2026)
- 12.11.4 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 12.11.5 GenScript ProBio Co.,Ltd. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst